BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kobayashi A, Miwa S, Nakata T, Miyagawa S. Disease recurrence patterns after R0 resection of hilar cholangiocarcinoma. Br J Surg. 2010;97:56-64. [PMID: 19937985 DOI: 10.1002/bjs.6788] [Cited by in Crossref: 72] [Cited by in F6Publishing: 77] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Irwin D. Update on Cholangiocarcinoma. Digestive Disease Interventions 2022;06:209-218. [DOI: 10.1055/s-0042-1751238] [Reference Citation Analysis]
2 Sinnamon AJ, Wood AC, Satyadi MA, Levitt CV, Hardy O, Haider M, Kim RD, Anaya DA, Denbo JW. Anatomic patterns of recurrence in biliary tract cancers: does primary tumor site matter? J Gastrointest Oncol 2022;13:1413-22. [PMID: 35837169 DOI: 10.21037/jgo-21-868] [Reference Citation Analysis]
3 Liu Z, Chen W, Wang Z, Liu X, Fan H, Xu L, Pan Y, Zhong S, Xie D, Bai J, Jiang Y, Zhang Y, Dai H, Chen Z. Development and Validation of a Prognostic Model to Predict Recurrence-Free Survival After Curative Resection for Perihilar Cholangiocarcinoma: A Multicenter Study. Front Oncol 2022;12:849053. [DOI: 10.3389/fonc.2022.849053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Namn Y, Bucobo JC. Cholangiocarcinoma: Epidemiology, Pathogenesis, and Prognosis. Hepato-Pancreato-Biliary Malignancies 2022. [DOI: 10.1007/978-3-030-41683-6_13] [Reference Citation Analysis]
5 Abdelrahim M, Esmail A, Abudayyeh A, Murakami N, Saharia A, McMillan R, Victor D, Kodali S, Shetty A, Nolte Fong JV, Moore LW, Heyne K, Gaber AO, Ghobrial RM. Transplant Oncology: An Evolving Field in Cancer Care. Cancers (Basel) 2021;13:4911. [PMID: 34638395 DOI: 10.3390/cancers13194911] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]
6 Hau HM, Devantier M, Jahn N, Sucher E, Rademacher S, Seehofer D, Sucher R. Impact of Body Mass Index on Tumor Recurrence in Patients Undergoing Liver Resection for Perihilar Cholangiocarcinoma (pCCA). Cancers (Basel) 2021;13:4772. [PMID: 34638257 DOI: 10.3390/cancers13194772] [Reference Citation Analysis]
7 Ahmed O, Vachharajani N, Chang SH, Park Y, Khan AS, Chapman WC, Doyle MBM. Single-center experience of liver transplantation for perihilar cholangiocarcinoma. HPB (Oxford) 2021:S1365-182X(21)01584-7. [PMID: 34465528 DOI: 10.1016/j.hpb.2021.08.940] [Reference Citation Analysis]
8 Soares KC, Jarnagin WR. The Landmark Series: Hilar Cholangiocarcinoma. Ann Surg Oncol 2021;28:4158-70. [PMID: 33829358 DOI: 10.1245/s10434-021-09871-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
9 Cambridge WA, Fairfield C, Powell JJ, Harrison EM, Søreide K, Wigmore SJ, Guest RV. Meta-analysis and Meta-regression of Survival After Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma.Ann Surg. 2021;273:240-250. [PMID: 32097164 DOI: 10.1097/SLA.0000000000003801] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 37.0] [Reference Citation Analysis]
10 Sakata J, Nomura T, Aono T, Kitami C, Yokoyama N, Minagawa M, Takizawa K, Miura K, Hirose Y, Ichikawa H, Nagahashi M, Shimada Y, Kobayashi T, Wakai T. Oncological outcomes of surgery for recurrent biliary tract cancer: who are the best candidates? HPB (Oxford) 2021:S1365-182X(21)00016-2. [PMID: 33558069 DOI: 10.1016/j.hpb.2021.01.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Namn Y, Bucobo JC. Cholangiocarcinoma: Epidemiology, Pathogenesis, and Prognosis. Hepato-Pancreato-Biliary Malignancies 2021. [DOI: 10.1007/978-3-030-37482-2_13-1] [Reference Citation Analysis]
12 Geers J, Jaekers J, Topal H, Aerts R, Vandoren C, Vanden Boer G, Topal B. Predictors of survival after surgery with curative intent for perihilar cholangiocarcinoma. World J Surg Oncol 2020;18:286. [PMID: 33143698 DOI: 10.1186/s12957-020-02060-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Le VH, O'Connor VV, Li D, Melstrom LG, Fong Y, DiFronzo AL. Outcomes of neoadjuvant therapy for cholangiocarcinoma: A review of existing evidence assessing treatment response and R0 resection rate. J Surg Oncol 2021;123:164-71. [PMID: 32974932 DOI: 10.1002/jso.26230] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
14 Johnston CJ, Healey AJ. Malignant liver tumours. Surgery (Oxford) 2020;38:480-6. [DOI: 10.1016/j.mpsur.2020.06.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Nakahashi K, Ebata T, Yokoyama Y, Igami T, Mizuno T, Yamaguchi J, Onoe S, Watanabe N, Nagino M. How long should follow-up be continued after R0 resection of perihilar cholangiocarcinoma? Surgery 2020;168:617-24. [PMID: 32665142 DOI: 10.1016/j.surg.2020.04.068] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
16 Sapisochin G, Ivanics T, Subramanian V, Doyle M, Heimbach JK, Hong JC. Multidisciplinary treatment for hilar and intrahepatic cholangiocarcinoma: A review of the general principles. Int J Surg 2020;82S:77-81. [PMID: 32380231 DOI: 10.1016/j.ijsu.2020.04.067] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
17 Nakanishi Y, Okamura K, Tsuchikawa T, Nakamura T, Noji T, Asano T, Matsui A, Tanaka K, Murakami S, Ebihara Y, Kurashima Y, Narasaki H, Amano T, Shichinohe T, Hirano S. Time to Recurrence After Surgical Resection and Survival After Recurrence Among Patients with Perihilar and Distal Cholangiocarcinomas. Ann Surg Oncol 2020;27:4171-80. [PMID: 32363510 DOI: 10.1245/s10434-020-08534-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
18 Ito T, Kuriyama N, Kozuka Y, Komatsubara H, Ichikawa K, Noguchi D, Hayasaki A, Fujii T, Iizawa Y, Kato H, Tanemura A, Murata Y, Kishiwada M, Mizuno S, Usui M, Sakurai H, Isaji S. High tumor budding is a strong predictor of poor prognosis in the resected perihilar cholangiocarcinoma patients regardless of neoadjuvant therapy, showing survival similar to those without resection. BMC Cancer 2020;20:209. [PMID: 32164621 DOI: 10.1186/s12885-020-6695-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
19 Kitano Y, Yamashita Y, Nakagawa S, Okabe H, Imai K, Chikamoto A, Baba H. Effectiveness of surgery for recurrent cholangiocarcinoma: A single center experience and brief literature review. The American Journal of Surgery 2020;219:175-80. [DOI: 10.1016/j.amjsurg.2019.02.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
20 Zhou C, Li H, Huang Q, Wang J, Gao K. Biliary self-expandable metallic stent combined with Iodine-125 seeds strand in the treatment of hilar malignant biliary obstruction. J Int Med Res 2020;48:300060519887843. [PMID: 31884851 DOI: 10.1177/0300060519887843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
21 Bird NT, Manu N, Quinn L, Needham A, Jones R, Fenwick S, Poston G, Palmer D, Malik H. Evaluation of the utility of prognostic models for patients with resected hilar cholangiocarcinoma. HPB 2019;21:1376-84. [DOI: 10.1016/j.hpb.2019.02.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Krampitz GW, Aloia TA. Staging of Biliary and Primary Liver Tumors. Surgical Oncology Clinics of North America 2019;28:663-83. [DOI: 10.1016/j.soc.2019.06.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Peng DZ, Lu J, Li B, Hu HJ, Ye XW, Xiong XZ, Cheng NS. A simple scoring system to predict early recurrence of Bismuth-Corlette type IV perihilar cholangiocarcinoma. Gastroenterol Rep (Oxf) 2019;7:345-53. [PMID: 31687154 DOI: 10.1093/gastro/goz012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
24 Khan AS, Dageforde LA. Cholangiocarcinoma. Surg Clin North Am. 2019;99:315-335. [PMID: 30846037 DOI: 10.1016/j.suc.2018.12.004] [Cited by in Crossref: 72] [Cited by in F6Publishing: 60] [Article Influence: 24.0] [Reference Citation Analysis]
25 Peng D, Lu J, Hu H, Li B, Ye X, Cheng N. Lymphocyte to Monocyte Ratio Predicts Resectability and Early Recurrence of Bismuth-Corlette Type IV Hilar Cholangiocarcinoma. J Gastrointest Surg. 2020;24:330-340. [PMID: 30671792 DOI: 10.1007/s11605-018-04086-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
26 Warner SG, Cho CS, Fong Y. Biliary Tract Tumors. Shackelford's Surgery of the Alimentary Tract, 2 Volume Set 2019. [DOI: 10.1016/b978-0-323-40232-3.00112-6] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
27 Ebata T, Hirano S, Konishi M, Uesaka K, Tsuchiya Y, Ohtsuka M, Kaneoka Y, Yamamoto M, Ambo Y, Shimizu Y, Ozawa F, Fukutomi A, Ando M, Nimura Y, Nagino M; Bile Duct Cancer Adjuvant Trial (BCAT) Study Group. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105:192-202. [PMID: 29405274 DOI: 10.1002/bjs.10776] [Cited by in Crossref: 172] [Cited by in F6Publishing: 185] [Article Influence: 43.0] [Reference Citation Analysis]
28 Horgan AM, Knox JJ. Adjuvant Therapy for Biliary Tract Cancers. JOP 2018;14:701-8. [DOI: 10.1200/jop.18.00558] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
29 Zhang XF, Beal EW, Chakedis J, Chen Q, Lv Y, Ethun CG, Salem A, Weber SM, Tran T, Poultsides G, Son AY, Hatzaras I, Jin L, Fields RC, Buettner S, Scoggins C, Martin RCG, Isom CA, Idrees K, Mogal HD, Shen P, Maithel SK, Schmidt CR, Pawlik TM. Defining Early Recurrence of Hilar Cholangiocarcinoma After Curative-intent Surgery: A Multi-institutional Study from the US Extrahepatic Biliary Malignancy Consortium. World J Surg 2018;42:2919-29. [PMID: 29404753 DOI: 10.1007/s00268-018-4530-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
30 Blaga MM, Brasoveanu V, Stroescu C, Ionescu M, Popescu I, Dumitrascu T. Pattern of the First Recurrence Has No Impact on Long-Term Survival after Curative Intent Surgery for Perihilar Cholangiocarcinomas. Gastroenterol Res Pract 2018;2018:2546257. [PMID: 30158963 DOI: 10.1155/2018/2546257] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
31 Bird NTE, McKenna A, Dodd J, Poston G, Jones R, Malik H. Meta-analysis of prognostic factors for overall survival in patients with resected hilar cholangiocarcinoma. Br J Surg. 2018;105:1408-1416. [PMID: 29999515 DOI: 10.1002/bjs.10921] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 7.3] [Reference Citation Analysis]
32 Braunwarth E, Stättner S, Fodor M, Cardini B, Resch T, Oberhuber R, Putzer D, Bale R, Maglione M, Margreiter C, Schneeberger S, Öfner D, Primavesi F. Surgical techniques and strategies for the treatment of primary liver tumours: hepatocellular and cholangiocellular carcinoma. Eur Surg 2018;50:100-12. [PMID: 29875798 DOI: 10.1007/s10353-018-0537-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
33 Motoyama H, Kobayashi A, Yokoyama T, Shimizu A, Sakai H, Notake T, Fukushima K, Miyagawa SI. Treatment with specific soluble factors promotes the functional maturation of transcription factor-mediated, pancreatic transdifferentiated cells. PLoS One 2018;13:e0197175. [PMID: 29768476 DOI: 10.1371/journal.pone.0197175] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
34 Komaya K, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, Yamaguchi J, Nagino M. Recurrence after curative-intent resection of perihilar cholangiocarcinoma: analysis of a large cohort with a close postoperative follow-up approach. Surgery 2018;163:732-8. [PMID: 29336813 DOI: 10.1016/j.surg.2017.08.011] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 14.0] [Reference Citation Analysis]
35 Reames BN, Pawlik TM. Hilar Cholangiocarcinoma. Surgical Diseases of the Pancreas and Biliary Tree 2018. [DOI: 10.1007/978-981-10-8755-4_14] [Reference Citation Analysis]
36 Kitano Y, Okabe H, Yamashita YI, Nakagawa S, Saito Y, Umezaki N, Tsukamoto M, Yamao T, Yamamura K, Arima K, Kaida T, Miyata T, Mima K, Imai K, Hashimoto D, Komohara Y, Chikamoto A, Ishiko T, Baba H. Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic cholangiocarcinoma. Br J Cancer 2018;118:171-80. [PMID: 29123259 DOI: 10.1038/bjc.2017.401] [Cited by in Crossref: 66] [Cited by in F6Publishing: 69] [Article Influence: 13.2] [Reference Citation Analysis]
37 Motoyama H, Kobayashi A, Yokoyama T, Shimizu A, Kitagawa N, Notake T, Fukushima K, Masuo H, Yoshizawa T, Miyagawa S. Survival Benefits of Surgical Resection in Patients with Recurrent Biliary Tract Carcinoma. World J Surg 2017;41:2817-29. [DOI: 10.1007/s00268-017-4107-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
38 Leng KM, Liu YP, Wang ZD, Zhong XY, Liao GQ, Kang PC, Cui YF, Jiang XM. Results of adjuvant radiation therapy for locoregional perihilar cholangiocarcinoma after curative intent resection. Onco Targets Ther 2017;10:2257-66. [PMID: 28461760 DOI: 10.2147/OTT.S131873] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
39 S Mahajan M, Moorthy S, P Karumathil S, Rajeshkannan R, Pothera R. CT Evaluation of Disease Pattern in Hilar Cholangiocarcinoma. IJRRT 2017;2. [DOI: 10.15406/ijrrt.2017.02.00020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
40 Kyrochristos ID, Glantzounis GK, Ziogas DE, Gizas I, Schizas D, Lykoudis EG, Felekouras E, Machairas A, Katsios C, Liakakos T, Cho WC, Roukos DH. From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers. Int J Mol Sci 2017;18:E180. [PMID: 28106782 DOI: 10.3390/ijms18010180] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
41 Kim YS, Jeong CY, Song HN, Kim TH, Kim HJ, Lee YJ, Hong SC. The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection. Chin J Cancer 2017;36:9. [PMID: 28086990 DOI: 10.1186/s40880-017-0182-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
42 Schoellhammer HF, Fong Y, Singh G. Extrahepatic bile duct tumors. Blumgart's Surgery of the Liver, Biliary Tract and Pancreas, 2-Volume Set 2017. [DOI: 10.1016/b978-0-323-34062-5.00051-0] [Reference Citation Analysis]
43 Miyazaki Y, Kokudo T, Amikura K, Kageyama Y, Takahashi A, Ohkohchi N, Sakamoto H. Survival of surgery for recurrent biliary tract cancer: a single-center experience and systematic review of literature. Japanese Journal of Clinical Oncology 2017;47:206-12. [DOI: 10.1093/jjco/hyw182] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
44 Bhardwaj N, Garcea G, Dennison AR, Maddern GJ. The Surgical Management of Klatskin Tumours: Has Anything Changed in the Last Decade? World J Surg 2015;39:2748-56. [PMID: 26133907 DOI: 10.1007/s00268-015-3125-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
45 Mansour JC, Aloia TA, Crane CH, Heimbach JK, Nagino M, Vauthey JN. Hilar cholangiocarcinoma: expert consensus statement. HPB (Oxford). 2015;17:691-699. [PMID: 26172136 DOI: 10.1111/hpb.12450] [Cited by in Crossref: 215] [Cited by in F6Publishing: 283] [Article Influence: 35.8] [Reference Citation Analysis]
46 Hartog H, Ijzermans JN, van Gulik TM, Koerkamp BG. Resection of Perihilar Cholangiocarcinoma. Surgical Clinics of North America 2016;96:247-67. [DOI: 10.1016/j.suc.2015.12.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
47 Hu HJ, Mao H, Shrestha A, Tan YQ, Ma WJ, Yang Q, Wang JK, Cheng NS, Li FY. Prognostic factors and long-term outcomes of hilar cholangiocarcinoma: A single-institution experience in China. World J Gastroenterol 2016; 22(8): 2601-2610 [PMID: 26937148 DOI: 10.3748/wjg.v22.i8.2601] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 47] [Article Influence: 7.2] [Reference Citation Analysis]
48 Chen Y, Li H, Jiang X, Chen D, Ni J, Sun H, Luo J, Yao H, Xu L. Regional thermochemotherapy versus hepatic arterial infusion chemotherapy for palliative treatment of advanced hilar cholangiocarcinoma: a retrospective controlled study.Eur Radiol. 2016;26:3500-3509. [PMID: 26822373 DOI: 10.1007/s00330-016-4208-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
49 Wagner A, Wiedmann M, Tannapfel A, Mayr C, Kiesslich T, Wolkersdörfer GW, Berr F, Hauss J, Witzigmann H. Neoadjuvant Down-Sizing of Hilar Cholangiocarcinoma with Photodynamic Therapy--Long-Term Outcome of a Phase II Pilot Study. Int J Mol Sci 2015;16:26619-28. [PMID: 26561801 DOI: 10.3390/ijms161125978] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
50 Groot Koerkamp B, Wiggers JK, Allen PJ, Besselink MG, Blumgart LH, Busch OR, Coelen RJ, D'Angelica MI, DeMatteo RP, Gouma DJ, Kingham TP, Jarnagin WR, van Gulik TM. Recurrence Rate and Pattern of Perihilar Cholangiocarcinoma after Curative Intent Resection. J Am Coll Surg. 2015;221:1041-1049. [PMID: 26454735 DOI: 10.1016/j.jamcollsurg.2015.09.005] [Cited by in Crossref: 92] [Cited by in F6Publishing: 99] [Article Influence: 13.1] [Reference Citation Analysis]
51 Lee JG, Lee SH, Lim JH, Park JS, Yoon DS, Kim KS. Is Pancreaticoduodenectomy Feasible for Recurrent Remnant Bile Duct Cancer Following Bile Duct Segmental Resection? J Gastrointest Surg 2015;19:2138-45. [DOI: 10.1007/s11605-015-2927-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
52 Takahashi Y, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, Nimura Y, Nagino M. Surgery for Recurrent Biliary Tract Cancer: A Single-center Experience With 74 Consecutive Resections. Ann Surg. 2015;262:121-129. [PMID: 25405563 DOI: 10.1097/sla.0000000000000827] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 7.3] [Reference Citation Analysis]
53 Choi SB, Han HJ, Park PJ, Kim WB, Song TJ, Kim JS, Suh SO, Choi SY. Disease Recurrence Patterns and Analysis of Clinicopathological Prognostic Factors for Recurrence after Resection for Distal Bile Duct Cancer. The American Surgeon 2015;81:289-296. [DOI: 10.1177/000313481508100332] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
54 Xu M, Brown RS. Liver Transplantation for the Referring Physician. Clinics in Liver Disease 2015;19:135-53. [DOI: 10.1016/j.cld.2014.09.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
55 Groot Koerkamp B, Fong Y. Outcomes in biliary malignancy. J Surg Oncol. 2014;110:585-591. [PMID: 25250887 DOI: 10.1002/jso.23762] [Cited by in Crossref: 55] [Cited by in F6Publishing: 61] [Article Influence: 6.9] [Reference Citation Analysis]
56 Xiang S, Lau WY, Chen XP. Hilar cholangiocarcinoma: controversies on the extent of surgical resection aiming at cure. Int J Colorectal Dis. 2015;30:159-171. [PMID: 25376337 DOI: 10.1007/s00384-014-2063-z] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
57 Zaydfudim VM, Rosen CB, Nagorney DM. Hilar cholangiocarcinoma. Surg Oncol Clin N Am 2014;23:247-63. [PMID: 24560109 DOI: 10.1016/j.soc.2013.10.005] [Cited by in Crossref: 35] [Cited by in F6Publishing: 85] [Article Influence: 4.4] [Reference Citation Analysis]
58 Weiss MJ, Cosgrove D, Herman JM, Rastegar N, Kamel I, Pawlik TM. Multimodal treatment strategies for advanced hilar cholangiocarcinoma. Langenbecks Arch Surg. 2014;399:679-692. [PMID: 24962146 DOI: 10.1007/s00423-014-1219-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
59 Soares KC, Kamel I, Cosgrove DP, Herman JM, Pawlik TM. Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobiliary Surg Nutr. 2014;3:18-34. [PMID: 24696835 DOI: 10.3978/j.issn.2304-3881.2014.02.05] [Cited by in F6Publishing: 59] [Reference Citation Analysis]
60 Popescu I, Dumitrascu T. Curative-intent surgery for hilar cholangiocarcinoma: prognostic factors for clinical decision making. Langenbecks Arch Surg 2014;399:693-705. [PMID: 24841192 DOI: 10.1007/s00423-014-1210-x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 4.5] [Reference Citation Analysis]
61 Furusawa N, Kobayashi A, Yokoyama T, Shimizu A, Motoyama H, Miyagawa S. Surgical Treatment of 144 Cases of Hilar Cholangiocarcinoma Without Liver-Related Mortality. World J Surg 2014;38:1164-76. [DOI: 10.1007/s00268-013-2394-x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 4.2] [Reference Citation Analysis]
62 Natsume S, Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, Nagino M. Hepatopancreatoduodenectomy for anastomotic recurrence from residual cholangiocarcinoma: report of a case. Surg Today 2014;44:952-6. [PMID: 23702706 DOI: 10.1007/s00595-013-0578-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
63 Kim K, Min HS, Chie EK, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Jang JJ, Ha SW. CD24 expression predicts distant metastasis in extrahepatic bile duct cancer. World J Gastroenterol 2013; 19(9): 1438-1443 [PMID: 23539485 DOI: 10.3748/wjg.v19.i9.1438] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
64 Tamoto E, Hirano S, Tsuchikawa T, Tanaka E, Miyamoto M, Matsumoto J, Kato K, Shichinohe T. Portal vein resection using the no-touch technique with a hepatectomy for hilar cholangiocarcinoma. HPB (Oxford). 2014;16:56-61. [PMID: 23461754 DOI: 10.1111/hpb.12067] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 4.8] [Reference Citation Analysis]
65 Dumitrascu T, Chirita D, Ionescu M, Popescu I. Resection for hilar cholangiocarcinoma: analysis of prognostic factors and the impact of systemic inflammation on long-term outcome. J Gastrointest Surg. 2013;17:913-924. [PMID: 23319395 DOI: 10.1007/s11605-013-2144-2] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 6.1] [Reference Citation Analysis]
66 Liu QD, Chen JZ, Xu XY, Zhang T, Zhou NX. Incidence of port-site metastasis after undergoing robotic surgery for biliary malignancies. World J Gastroenterol 2012; 18(40): 5695-5701 [PMID: 23155309 DOI: 10.3748/wjg.v18.i40.5695] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
67 Darwish Murad S, Kim WR, Therneau T, Gores GJ, Rosen CB, Martenson JA, Alberts SR, Heimbach JK. Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. Hepatology 2012;56:972-81. [PMID: 22290335 DOI: 10.1002/hep.25629] [Cited by in Crossref: 100] [Cited by in F6Publishing: 154] [Article Influence: 10.0] [Reference Citation Analysis]
68 Kim K, Chie EK, Jang J, Kim SW, Han S, Oh D, Im S, Kim T, Bang Y, Ha SW. Distant Metastasis Risk Stratification for Patients Undergoing Curative Resection Followed by Adjuvant Chemoradiation for Extrahepatic Bile Duct Cancer. International Journal of Radiation Oncology*Biology*Physics 2012;84:81-7. [DOI: 10.1016/j.ijrobp.2011.10.059] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
69 Jung SJ, Woo SM, Park HK, Lee WJ, Han MA, Han SS, Kim SH, Park SJ, Kim TH, Koh YH, Hong EK. Patterns of initial disease recurrence after resection of biliary tract cancer. Oncology 2012;83:83-90. [PMID: 22777276 DOI: 10.1159/000339695] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
70 Darwish Murad S, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM, Botha JF, Mezrich JD, Chapman WC, Schwartz JJ, Hong JC, Emond JC, Jeon H, Rosen CB, Gores GJ, Heimbach JK. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012; 143: 88-98. quiz e14. [PMID: 22504095 DOI: 10.1053/j.gastro.2012.04.008] [Cited by in Crossref: 362] [Cited by in F6Publishing: 433] [Article Influence: 36.2] [Reference Citation Analysis]
71 Lee JH, Hwang DW, Lee SY, Park K, Lee Y. The Proximal Margin of Resected Hilar Cholangiocarcinoma: The Effect of Microscopic Positive Margin on Long-Term Survival. The American Surgeon 2012;78:471-7. [DOI: 10.1177/000313481207800440] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
72 Song SC, Heo JS, Choi DW, Choi SH, Kim WS, Kim MJ. Survival benefits of surgical resection in recurrent cholangiocarcinoma. J Korean Surg Soc 2011;81:187-94. [PMID: 22066120 DOI: 10.4174/jkss.2011.81.3.187] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
73 Chung MJ, Lee KJ, Bang S, Park SW, Kim KS, Lee WJ, Song SY, Chung JB, Park JY. Preoperative serum CA 19-9 level as a predictive factor for recurrence after curative resection in biliary tract cancer. Ann Surg Oncol. 2011;18:1651-1656. [PMID: 21210227 DOI: 10.1245/s10434-010-1529-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
74 Schlitter AM, Esposito I. Definition of microscopic tumor clearance (r0) in pancreatic cancer resections. Cancers (Basel). 2010;2:2001-2010. [PMID: 24281214 DOI: 10.3390/cancers2042001] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 5.1] [Reference Citation Analysis]
75 Shimada M, Sugimoto K, Iwahashi S, Utsunomiya T, Morine Y, Imura S, Ikemoto T. CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma. J Gastroenterol 2010;45:896-902. [DOI: 10.1007/s00535-010-0235-3] [Cited by in Crossref: 52] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
76 Bubna A, Prabhala NR. When Bookbuilding Meets IPOs. SSRN Journal. [DOI: 10.2139/ssrn.972757] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Reference Citation Analysis]